# US 6,297,019 B1 · Recombinant polynucleotides encoding CYP7 promoter-binding factors > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,297,019 B1 - Document ID: US6297019B1 - Status: Granted - Kind: B1 - Application number: 09/510,654 - Filed: 2000-02-22 - Granted: 2001-10-02 - Earliest claimed: 1997-12-08 - Assignees: Tularik Inc.; Sumitomo Pharmaceuticals Company, Limited - Inventors: Bei Shan; Masahiro Nitta - Web page: https://patentgrep.com/patent/US6297019B1 ## CPC - C07K 14/4705: {stimulating, promoting or activating activity} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention provides methods and compositions relating to CPF proteins which regulate transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed CPF encoding nucleic acids or purified from human cells. The invention provides isolated CPF hybridization probes and primers capable of specifically hybridizing with the disclosed CPF genes, CPF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry. ## Claims ### Claim 1 A recombinant polynucleotide comprising a cDNA which comprises a coding region encoding a polypeptide comprising: (a) SEQ ID NO:2, 4, or 6, or (b) at least ten contiguous amino acid residues of SEQ ID NO:2 comprising at least one sequence selected from the group consisting of amino acid residues 1-10, 11-15 and 16-21 of SEQ ID NO:2, or (c) at least ten contiguous amino acid residues of SEQ ID NO:6 comprising at least one sequence selected from the group consisting of amino acid residues 3-10, 13-22 and 30-38 of SEQ ID NO:6, wherein said cDNA is flanked by a sequence other than that which it is joined to on a natural chromosome. ### Claim 2 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least ten contiguous amino acid residues of SEQ ID NO:2 comprising at least one sequence selected from the group consisting of amino acid residues 1-10, 11-15, and 16-21, or at least ten contiguous amino acid residues of SEQ ID NO:6 comprising at least one sequence selected from the group consisting of amino acid residues 3-10, 13-22 and 30-38 of SEQ ID NO:6. ### Claim 3 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least one sequence selected from the group consisting of amino acid residues 1-10, 4-15, 8-20, 12-25, 15-30, 19-32, 20-29 and 200-211 of SEQ ID NO:2. ### Claim 4 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least one sequence selected from the group consisting of amino acid residues 33-123, 242-333 and 383-405 of SEQ ID NO:2. ### Claim 5 A recombinant polynucleotide comprising a coding region encoding a polypeptide comprising at least ten contiguous amino acid residues of SEQ ID NO:4 comprising amino acid residues 150-159 of SEQ ID NO:4. ### Claim 6 (depends on 1) A polynucleotide according to claim 1, said polypeptide, comprising at least 16 contiguous amino acid residues of SEQ ID NO:2 comprising at least one sequence selected from the group consisting of amino acid residues 1-10, 11-15, 16-21, and 204-207 of SEQ ID NO:2. ### Claim 7 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least 32 contiguous amino acid residues of SEQ ID NO:2 comprising at least one sequence selected from the group consisting of amino acid residues 1-10, 11-15, 16-21, 204-207 and 299-307 of SEQ ID NO:2. ### Claim 8 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least 64 contiguous amino acid residues of SEQ ID NO:2 comprising at least one sequence selected from the group consisting of amino acid residues 1-10, 11-15, 16-21, 204-207 and 299-307 of SEQ ID NO:2. ### Claim 9 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least 16 contiguous amino acid residues of SEQ ID NO:4 comprising amino acid residue 154 of SEQ ID NO:4. ### Claim 10 A recombinant polynucleotide comprising a cDNA which comprises a coding region encoding a polynucleotide comprising at least 32 contiguous amino acid residues of SEQ ID NO:4 comprising amino acid residue 154 of SEQ ID NO:4, wherein said cDNA is flanked by a sequence other than that which it is joined to on a natural chromosome. ### Claim 11 (depends on 10) A polynucleotide according to claim 10, said polypeptide comprising at least 64 contiguous amino acid residues of SEQ ID NO:4 comprising amino acid residue 154 of SEQ ID NO:4. ### Claim 12 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least 16 contiguous amino acid residues of SEQ ID NO:6 comprising at least one sequence selected from the group consisting of amino acid residues 3-10, 13-22 and 30-38 of SEQ ID NO:6. ### Claim 13 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least 32 contiguous amino acid residues of SEQ ID NO:6 comprising at least one sequence selected from the group consisting of amino acid residues 3-10, 13-22 and 30-38 of SEQ ID NO:6. ### Claim 14 (depends on 1) A polynucleotide according to claim 1, said polypeptide comprising at least 64 contiguous amino acid residues of SEQ ID NO:6 comprising at least one sequence selected from the group consisting of amino acid residues 3-10, 13-22 and 30-38 of SEQ ID NO:6. ### Claim 15 (depends on 1) A polynucleotide according to claim 1, wherein said polypeptide specifically binds the CYP7 gene promoter. ### Claim 16 (depends on 1) A method of screening comprising the steps of: translating a polynucleotide according to claim 1 to produce the polypeptide; incubating in vitro or in culture a mixture comprising: the polypeptide, a binding target of said polypeptide, and a candidate agent, under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity; and detecting the binding affinity of said polypeptide to said binding target to determine an agent-biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said polypeptide to said binding target. ### Claim 17 (depends on 16) A method according to claim 16, wherein the binding target is a nucleic acid comprising a CYP7 promoter sequence sufficient to specifically bind the polypeptide. ### Claim 18 (depends on 1) A method of screening, said method comprising the steps of: translating a polynucleotide according to claim 1 to produce the polypeptide; incubating in vitro or in culture a mixture comprising the polypeptide and a candidate agent under conditions whereby said agent specifically binds said polypeptide; and detecting the specifically bound agent. ### Claim 19 A recombinant polynucleotide comprising a cDNA which comprises a sequence selected from, (a) the group consisting of SEQ ID NO:1, 3 and 5 or (b) the group consisting of nucleotides 1-26, 52-62, 1630-1650, 1790-1810, 1855-1875, 1910-1925, 2566-2586, and 2666-2686 of SEQ ID NO:1, wherein said cDNA is flanked by a sequence other than that which it is joined to on a natural chromosome. ### Claim 20 (depends on 19) A recombinant polynucleotide according to claim 19 comprising a sequence selected from the group consisting of SEQ ID NO:1, 3 and 5.